Research programme: calcium channel modulators - Pascal Biosciences

Drug Profile

Research programme: calcium channel modulators - Pascal Biosciences

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioMmune Technologies; University of British Columbia
  • Developer Pascal Biosciences; University of British Columbia
  • Class
  • Mechanism of Action Calcium channel modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Infections

Most Recent Events

  • 30 Mar 2017 ​BioMmune Technologies is now called Pascal Biosciences
  • 29 Jun 2016 BioMmune Technologies has patent protection for monoclonal antibodies that modulate voltage gated calcium channels in China
  • 03 Mar 2014 Early research in Autoimmune disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top